All News
Alive in 2025 (1.10.2025)
Dr. Jack Cush brings in the new year with a review of the latest from RheumNow.com
Read Article
EULAR: Considerations when Transitioning from Pediatric to Adult Rheumatologic Care
EULAR has established guidance on best practices for delivering patient education in physical activity and self-management of pain during transitional care in rheumatology.
Prevalence of Autoimmune Diseases in the United States
An epidemiologic assessment of the prevalence of autoimmune diseases in the United States (US) finds that nearly 5% of the population has an autoimmune disorder, twice as many in women compared to men.
Read Article
ICYMI: VITAL Info on Autoimmune Disease (2.9.2024)
Dr. Jack Cush reviews the journal reports from the past week on RheumNow.com. Highlights are summarized by three songs: "Stairway to Heaven", "You're No Good", and "How Long (has this been going on)".
Read Article
VA (Veterans) study of 531 RA-ILD (among 9,701 incident RA) vs 68,852 matched controls - finds exposure to fire smoke PM2.5 assoc w/ RA-ILD/aOR 1.98 (but not RA). NOx, ozone, and PM10 assoc w/ seroneg. RA risk (aOR 1.16-1.25) . Pollution increases risk of RA & RA-ILD… https://t.co/AuG4rRtx4r https://t.co/XyHtjrSfhi
Dr. John Cush RheumNow ( View Tweet)
Leeds study of 19 pts at-risk for RA (ACPA+ & arthralgia) finds low-diversity gut microbiome & in the 10 mos preceding the transition to RA, microbiome becomes more unstable w/ accumulation of Prevotellaceae, particularly Prevotella copri https://t.co/Va9Z0NWHj9 https://t.co/ciM7QtEF5S
Dr. John Cush RheumNow ( View Tweet)
In #RA, Higher levels of ESR and CRP, but not DAS28, joint counts or global assessments, were significantly associated with the risk of incident ILD in RA. German biologics (RABBIT) registry study compared 139 RA-ILD vs vs 686 controls. https://t.co/IB7aS6IKgT https://t.co/0zN5N7w65l
Dr. John Cush RheumNow ( View Tweet)
Real world observations from 65 RA-ILD pts Rx w/ nintendinb (95% on DMARDs/Pred) in Italian GISEA registry. 12 mos retention rate = 77% & was effective ~80% in pts w/ > 6 months F/U. Side effects in 55% (mainly GI) & ~1/2 had to reduce dose. 23% D/C drug for AE.… https://t.co/aVcIYtoMK4 https://t.co/CBHxzBc9XQ
Dr. John Cush RheumNow ( View Tweet)
Review of of nurse-led care (NLC) vs Rheum-led (RLC) vs Usual care in RA pts - 14 studies, 3369 pts. shows NLC proves highly effective in managing RA patients, surpassing usual care and equating to rheumatologist-led care in primary and secondary outcomes.… https://t.co/evpFTT9n22 https://t.co/n8ncKG9SFt
Dr. John Cush RheumNow ( View Tweet)
Phase 3 Trial Results of Deucravacitinib in Psoriatic Arthritis
Bristol Myers Squibb announced recently the results from POETYK PsA-1 and POETYK PsA-2, Phase 3 trials pivotal trials of deucravacitinib (DEUC) in adults with active psoriatic arthritis (PsA).… https://t.co/yKBV91dR8z https://t.co/nndnpYheNu
Dr. John Cush RheumNow ( View Tweet)
In #RA, Higher levels of ESR and CRP, but not DAS28, joint counts or global assessments, were significantly associated with the risk of incident ILD in RA. German biologics (RABBIT) registry study compared 139 RA-ILD vs vs 686 controls. https://t.co/Ul4HZ1hzS0 https://t.co/GLKL7U4ASt
Dr. John Cush RheumNow ( View Tweet)
Leeds study of 19 pts at-risk for RA (ACPA+ & arthralgia) finds low-diversity gut microbiome & in the 10 mos preceding the transition to RA, microbiome becomes more unstable w/ accumulation of Prevotellaceae, particularly Prevotella copri https://t.co/rbYMCl1FcO https://t.co/LWqppg36cn
Dr. John Cush RheumNow ( View Tweet)
UKs University of Birmingham researchers have just been awarded £3.5 million funding from Johnson & Johnson to investigate mechanisms of response and non-response to biologic and targeted synthetic therapies in rheumatoid arthritis. https://t.co/or9amYqljz https://t.co/EvDhVfqOig
Dr. John Cush RheumNow ( View Tweet)
RheumNow Live 2025 kicks off in just 6 weeks! Join us Feb 8-9 in Dallas for an unmatched rheumatology event.
https://t.co/VH2ahP1XUy
Don’t miss expert insights on JAK Inhibitors from:
🔹 Madelaine Feldman, MD
🔹 Joseph F. Merola, MD
🔹 Christina Charles-Schoeman, MD… https://t.co/9dRVwLNufF https://t.co/r88g6QMBC3
Links:
Dr. John Cush RheumNow ( View Tweet)
Italian study of 458 #RA pts shows 16% (71)meeting the EULAR criteria for difficult 2 Rx RA ( D2T-RA); unrelated to age, gender, seropositivity. BUT D2T-RA was assoc w/ erosions (24% vs 11%), obesity (33% vs 19%) & FM (25% vs 10%) https://t.co/w5mliNkfBT https://t.co/m65jk62wmh
Dr. John Cush RheumNow ( View Tweet)
Zhang @jeffsparks et al. Even more evidence that MTX does not cause ILD, and in fact prevents ILD, in RA, OR 0.48 in meta-analysis. @RheumNow #ACR24 Abstr#1384 https://t.co/w5G1dEF7Vm https://t.co/cyiQqGBf01 https://t.co/r909qqIh4V
Links:
Dr. John Cush RheumNow ( View Tweet)
Seronegative RA: sometimes there's an assumption that they'll eventually get a 'real' diagnosis
at @MayoClinic, 85% of patients diagnosed with seronegative RA kept their diagnosis at 10 years.
Usually, seroneg RA means seroneg RA!
#ACR24 @MyasoedovaElena ABST0458 @RheumNow… https://t.co/lJ95hYO3vM https://t.co/zF9esDnLYh
Dr. John Cush RheumNow ( View Tweet)
Outcomes Comparison study of late-onset RA (LORA) vs younger-onset RA (YORA) showed similar Dz activity assessments over 5 years but Late onset RA had worse functional outcomes and more adverse events (adj HR 4.7 for death & 2.6 for malignancy). https://t.co/b58zJG1OuA https://t.co/WZa12O06Rf
Dr. John Cush RheumNow ( View Tweet)
A re-evaluation of lupus arthritis. Old dogma is RA is erosive and SLE non-erosive. With better imaging, lupus arthritis can be erosive. Vivianne Malstrom. @RheumNow #ACR24 https://t.co/dFRnmGMGls https://t.co/LNoCtmtVuI
Links:
Dr. John Cush RheumNow ( View Tweet)
Algorithm for the treatment of calcinosis #calcinosis @RheumNow #ACR24 https://t.co/NZhP7Enzrp https://t.co/1mO8waM5DI
Links:
Dr. John Cush RheumNow ( View Tweet)
